Thursday, October 23, 2025

2:30 PM - 3:15 PM

---

Details

Successful risk management in drug development involves strategic planning, early identification of potential issues, and proactive mitigation strategies. While managing risk and failure in early-stage drug development is crucial to ensuring the safety, efficacy, financial viability of new treatments and overall project success, Venture capital investment and ASX listed companies carry their own unique risk profile due to the nature of biotech startups and early-stage companies when they go public. This project risk can be amplified when investment is made in novel drug targets and emerging technologies where there limited clinical or regulator precedent. VC investors and public company CEO’s and boards mitigate these risks through diversification, thorough due diligence, and strategic portfolio management. This panel session will discuss what are the key elements of successful risk management in private and public biotech companies. Topics covered will include; • Early Risk Assessment • Technology and execution risk • Clinical safety and Adverse Effects • Regulatory Strategy. • Quality Risk Management • Portfolio, Operational, and Resource Risk Management. The panel will include biotech CEO’s who will share their real-life experience of failure first-hand and why are Australians so afraid to talk about failure.

---

Speaker